Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?
2026-07-14 14:24
•David Jagielski, Cpa •The Motley Fool
•••• • Axe Capital view
Pfizer’s High Dividend: Opportunity or Red Flag?
Pfizer offers a rare 7.1% dividend yield, but questions linger over its sustainability amid earnings pressure.
Pfizer’s dividend yield dwarfs most in the S&P 500 at 7.1%, tempting income seekers hunting for yield in a low-return world. On paper, the yield looks juicy. However, the company’s diluted earnings per share—$0.47 versus the dividend payout of $0.43—leaves only a thin cushion. Pfizer is trying to shore up the dividend safety through aggressive cost-cutting and restructuring, which is a positive sign. Still, the looming patent cliffs pose a real threat to future sales and earnings stability. For South African investors, Pfizer isn’t an obvious pick given the lack of direct JSE equivalents and the currency risk in USD/ZAR. The rand’s recent weakness could amplify volatility in Pfizer’s local cost and repatriation of returns. Take this as a watch-and-wait scenario rather than a buy-at-all-costs story. If earnings falter further or patent risks materialize faster than expected, the dividend could be in danger. this is just my opinion and not financial advice
Given the risks and limited local hedging options, I’d watch Pfizer closely but hold off buying until earnings stabilize or restructuring shows clear payoff. Use USD/ZAR with caution around any exposure to help manage currency volatility.
- PFE
- USD/ZAR
- Patent cliffs reducing future earnings
- Rand volatility impacting USD-denominated returns
5/10
Pfizer's 7.1% dividend yield is the highest in the S&P 500, more than six times the average, raising concerns about sustainability. While the dividend currently appears safe with the company undergoing cost-cutting restructuring, earnings provide limited buffer with diluted per-share profit of $0.47 barely exceeding the quarterly dividend of $0.43. The stock trades at a low valuation of 8x estimated future earnings, potentially making it an underrated income option for investors willing to monitor it closely, though patent cliffs and future sales challenges pose risks.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: David Jagielski, Cpa
Categories: Rates, Equities, Earnings, Capital Returns
Tickers: PFE
Sentiment: Neutral - The article presents a balanced view of Pfizer as a potential income investment opportunity. While the exceptionally high dividend yield (7.1%) raises concerns about sustainability and there are legitimate risks from weak earnings buffers and patent cliffs, the company's restructuring efforts, cost-cutting measures, and low valuation (8x forward earnings) suggest the dividend is currently safe. The recommendation is cautiously positive for income investors willing to monitor the stock closely, but not without reservations.
Keywords: dividend yield, pharmaceutical, earnings, dividend safety, patent cliffs, cost restructuring, income investing, valuation
Insights:
- PFE: Neutral: The article presents a balanced view of Pfizer as a potential income investment opportunity. While the exceptionally high dividend yield (7.1%) raises concerns about sustainability and there are legitimate risks from weak earnings buffers and patent cliffs, the company's restructuring efforts, cost-cutting measures, and low valuation (8x forward earnings) suggest the dividend is currently safe. The recommendation is cautiously positive for income investors willing to monitor the stock closely, but not without reservations.